CD4 T cells in anti-viral immunity and immune pathology
CD4 T 细胞在抗病毒免疫和免疫病理学中的作用
基本信息
- 批准号:8652531
- 负责人:
- 金额:$ 236.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAntibody FormationAntigen PresentationAreaB-Lymphocyte SubsetsB-LymphocytesBiological ModelsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCell physiologyCellsCloningCollaborationsCommunicationComplexConsultationsEffector CellEpitopesGenerationsGoalsHIV InfectionsHumanHuman Herpesvirus 6ImmuneImmune responseImmune systemImmunityImmunologistImmunologyInfectionInfluenzaInfluenza A virusJointsKnowledgeLaboratoriesLesionLungLymphocytic choriomeningitis virusMHC Class II GenesMassachusettsMediatingMemoryMemory B-LymphocyteModelingMolecularNatural ImmunityNatural Killer CellsPathogenesisPathologyPeptide/MHC ComplexPropertyReagentRegulationResearchResearch PersonnelResearch Project GrantsResource SharingRespiratory Tract InfectionsRestRoleRouteScientistStructureSystemT cell responseT-Cell ReceptorT-LymphocyteT-Lymphocyte EpitopesT-Lymphocyte SubsetsTherapeuticTransgenic MiceTransgenic OrganismsTranslatingUnited States National Institutes of HealthUniversitiesVaccine DesignVaccinesVaccinia virusViralViral PathogenesisVirusVirus DiseasesWorkadaptive immunitycombatcross reactivitydata managementdesignimmunopathologyinfluenzavirusinsightinterestmedical schoolsmeetingsmemory CD4 T lymphocytemouse modelmucosal sitenew technologypathogenprogramsprophylacticrespiratoryresponsestemtechnology development
项目摘要
DESCRIPTION (provided by applicant): CD4 T cells have long been thought to be orchestrators of the rest of the immune system, but the past decade of CD4 T cell research has revealed many new functions and new subsets of CD4 T cells such that the interactions between these subsets and the rest of the immune system in regards to viral pathogenesis need to be examined. We propose here a collaborative U19 program in response to RFA-AI-12-048, Immune Mechanisms of Virus Control. The work proposed is highly consistent with the aims of the RFA, including (1) examining the interactions between innate and adaptive immune mechanisms in viral systems, (2) examining such actions at mucosal sites, in this case the lung, (3) examining how different T and B cell subsets are maintained after infection, and (4) defining the impact of multiple infections on viral immunity and pathogenesis. This U19 studies viruses of interest to this RFA, including Group 1 (HHV-6), Group 3A (LCMV, vaccinia virus), and Group 3C (influenza virus) pathogens. Further, our program uses mouse models that have provided valuable information regarding the immune response to viral infections, and it translates these findings into human immunology. This program is directed by Dr. Raymond Welsh and involves already collaborating scientists within one department (Pathology) at the University of Massachusetts Medical School (UMMS). It consists of four research projects, one administrative core, and two scientific cores that will provide reagents to the projects as well as pursue novel technology development. Project 1 (Dr. Welsh) examines the ability of NK cells to act as natural suppressors of CD4 T cells and regulate B cells and CD8 T cell-dependent pathology and persistence in the lung; Project 2 (Dr. Swain) examines how memory CD4 T cells alter both innate and adaptive immunity to influenza A virus and contribute to long term antibody responses; Project 3 (Dr. Selin) examines how CD4 and CD8 T cells cross-reactive between different viruses mediate detrimental heterologous immunity in the lung in mouse models and in human influenza subjects; Project 4 (Dr. Stern) examines how human HHV-6-specific CD4 T cell responses regulate and are regulated by CD8 cells and NK cells. These highly collaborative projects will rely on a core B (Dr. Stern), which will provide MHC reagents for T cell analyses, and a core C (Dr. Huseby), which will provide T cell receptor cloning and transgenic mice. This program will be coordinated by an administrative Core A (Dr. Welsh), which will arrange meetings, consultations, resource sharing, and provide statistical analysis and data management. This work should provide insights into how to best harness these properties in the design of vaccine strategies.
RELEVANCE: Infections of the respiratory track are among the leading cause of human illnesses, and they can be caused by many different viruses, which elicit strong immune responses and immunopathological lesions. This program project examines how CD4 T cells, considered the orchestrators of the immune system, interact with B cells, CD8 T cells, NK cells and the innate immune system to mediate or preclude virus-induced immunopathology. Knowledge gained form this study should help in the construction of vaccines and treatments for respiratory infections.
描述(由申请人提供):长期以来,CD4 T细胞一直被认为是其余免疫系统的编排者,但是CD4 T细胞研究的过去十年揭示了许多新功能和CD4 T细胞的新功能和新的子集,因此需要检查这些子集与其他免疫系统之间的相互作用。我们在这里提出了一个协作U19计划,以响应RFA-AI-12-048,即病毒控制的免疫机制。提出的工作与RFA的目的高度一致,包括(1)检查病毒系统中先天和适应性免疫机制之间的相互作用,(2)在肺部肺部检查此类作用,在这种情况下,在这种情况下,(3)检查感染后的T和B细胞群在感染后保持不同的T和B细胞群如何维持多种失败的影响,并定义了多种感染的影响。该U19研究了该RFA感兴趣的病毒,包括第1组(HHV-6),第3A组(LCMV,Vaccinia病毒)和3C组(流感病毒)病原体。此外,我们的程序使用的小鼠模型提供了有关对病毒感染的免疫反应的有价值信息,并将这些发现转化为人类免疫学。该计划由雷蒙德·威尔士(Raymond Welsh)博士指导,涉及马萨诸塞大学医学院(UMMS)的一个系(病理)中的科学家。它由四个研究项目,一个行政核心和两个科学核心组成,它们将为项目提供试剂以及追求新颖的技术开发。项目1(威尔士博士)研究了NK细胞充当CD4 T细胞自然抑制因子并调节B细胞的能力以及肺中CD8 T细胞依赖性病理和持久性的能力。项目2(Swain博士)研究了记忆CD4 T细胞如何改变先天性和适应性免疫,以使流感病毒并有助于长期抗体反应;项目3(Selin博士)研究了不同病毒之间的CD4和CD8 T细胞如何在小鼠模型和人类流感受试者中介导肺中有害异源免疫的交叉反应;项目4(Stern博士)研究了人类HHV-6特异性CD4 T细胞反应如何调节并由CD8细胞和NK细胞调节。这些高度协作的项目将依靠核心B(Stern博士),该项目将提供用于T细胞分析的MHC试剂,以及核心C(Huseby博士),该试剂将提供T细胞受体克隆和转基因小鼠。该计划将由行政核心A(威尔士博士)协调,该计划将安排会议,咨询,资源共享,并提供统计分析和数据管理。这项工作应提供有关如何最好地利用这些特性在疫苗策略设计中的见解。
相关性:呼吸道的感染是人类疾病的主要原因之一,它们可能是由许多不同的病毒引起的,这些病毒引起了强烈的免疫反应和免疫病理病变。该程序项目研究了CD4 T细胞如何考虑免疫系统的编排,与B细胞,CD8 T细胞,NK细胞和先天免疫系统相互作用,以介导或排除病毒诱导的免疫病理学。该研究获得的知识应有助于建造疫苗和呼吸道感染的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raymond M Welsh其他文献
Raymond M Welsh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Raymond M Welsh', 18)}}的其他基金
NK cell regulation of CD4 T cell responses
NK 细胞对 CD4 T 细胞反应的调节
- 批准号:
9226027 - 财政年份:2014
- 资助金额:
$ 236.85万 - 项目类别:
CD4 T cells in anti-viral immunity and immune pathology
CD4 T 细胞在抗病毒免疫和免疫病理学中的作用
- 批准号:
9443502 - 财政年份:2014
- 资助金额:
$ 236.85万 - 项目类别:
Effect of Virus Infections on the Maintenance of Transplantation Tolerance
病毒感染对移植耐受维持的影响
- 批准号:
8279392 - 财政年份:2011
- 资助金额:
$ 236.85万 - 项目类别:
Effect of Virus Infections on the Maintenance of Transplantation Tolerance
病毒感染对移植耐受维持的影响
- 批准号:
7994917 - 财政年份:2010
- 资助金额:
$ 236.85万 - 项目类别:
Recombinant Vaccinia Virus with Reduced Virulence
毒力降低的重组痘苗病毒
- 批准号:
7698922 - 财政年份:2008
- 资助金额:
$ 236.85万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
TNFRSF13B polymorphisms and immunity to transplantation
TNFRSF13B 多态性与移植免疫
- 批准号:
10734879 - 财政年份:2023
- 资助金额:
$ 236.85万 - 项目类别:
Reprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast Cancer
重编程外泌体用于三阴性乳腺癌的新型免疫疗法
- 批准号:
10733734 - 财政年份:2023
- 资助金额:
$ 236.85万 - 项目类别:
"Extended dosing" immunization to enhance humoral immunity to next-generation vaccines
“延长剂量”免疫增强对下一代疫苗的体液免疫
- 批准号:
10638732 - 财政年份:2023
- 资助金额:
$ 236.85万 - 项目类别:
Maturation of human humoral immunity through repeat malaria challenges
通过重复疟疾挑战使人体体液免疫成熟
- 批准号:
10720245 - 财政年份:2023
- 资助金额:
$ 236.85万 - 项目类别:
Role of the immunoglobulin DQ52 DH gene segment in fetal immunosuppression
免疫球蛋白 DQ52 DH 基因片段在胎儿免疫抑制中的作用
- 批准号:
10596627 - 财政年份:2022
- 资助金额:
$ 236.85万 - 项目类别: